The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Tranexamic acid (TXA) is a synthetic reversible competitive inhibitor to plasminogen lysine receptor, which prevents plasmin formation and stabilizes the fibrin matrix, thus reducing bleeding. While recent studies have demonstrated the antifibrinolytic benefits of TXA in obstetric and gynecologic conditions, traumatic hemorrhage, cardiac surgery, total knee arthroplasty, and more, there is a paucity of clinical data on TXA use in plastic surgery. The aim of this study is to evaluate the effect of local and systemic TXA on postoperative periocular ecchymosis/edema in orbital surgery.
Full description
Patients, who will be undergoing orbital surgery anyways, will be given the option to participate in the study. Informed consent will be obtained in clinic during the preoperative consultation. On the day of surgery in the preoperative suite, study participants will be randomly allocated to one of three groups via computer-generated random numbers:
Group 1: will receive 1g intravenous tranexamic acid (Pfizer, New York, NY) 20 minutes prior to surgery. Group 2: will receive 1.7 mL of subcutaneous tranexamic acid 100 mg/mL (Pfizer, New York, NY) with local anesthetic to the orbit two minutes prior to incision. Group 3: will receive intravenous normal saline and subcutaneous local anesthetic (i.e. standard procedure) as control group.
Twenty minutes before incision time, all patients will receive an intravenous solution. This will be either saline (placebo, participants in group 2 and 3) or 1g of tranexamic acid (participants in group 1). All operations will be performed using the standard of care technique and surgical instruments. All surgery will be performed under intravenous sedation with local anesthesia. Standard skin marking will be drawn, then the surgeon will inject each patient subcutaneously with either (1) a 5 cc mixture of TXA (100 mg/mL) mixed with 2% lidocaine with epinephrine and 0.5% marcaine with epinephrine in a 1:1:1 ratio (local TXA, Group 2) or (2) normal saline 0.9% sodium chloride mixed with 2% lidocaine with epinephrine and 0.5% marcaine with epinephrine in a 1:1:1 ratio (Group 1, Group 3). Degree of ecchymosis and edema in the postoperative photographs will be assessed separately by two graders. Graders will be blinded to treatment groups, and the photos will be completely deidentified.
Immediately following the procedure, the surgeon will take standardized photographs. The surgeon will also take standardized photographs at the regular 7-day postoperative visit. These photos will be deidentified and analyzed for degree of ecchymosis and edema by two blinded graders who will rate the photos using a standard five point grading scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = profound) as described in the respective outcome measures.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients undergoing orbital surgery (decompressions, fracture repairs, enucleations, eviscerations, etc.)
- Patients who are at least 18 years of age
- Patients that have the capacity to consent
Exclusion criteria
- Any history of previous orbital surgery
- Any patient undergoing multiple simultaneous periocular surgical procedures
- Any patient with active infection
- History of stroke or seizure
- History of bleeding/clotting disorder
- Patients who do not comply with the required postoperative follow-up schedule
- Patients who are allergic to tranexamic acid
- Patients who have taken anticoagulant/antiplatelet agents (including aspirin) within 7 days prior to surgery
- Patients who have periocular ecchymosis or edema prior to surgery
Trial design
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
Anne Barmettler
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal